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EDITOR’S CORRESPONDENCE
Statin-Related Myopathy
A s Hansen et al
1 noted in their report of out-
comes in patients with statin-associatedmyopa-
thy, their study is limited by retrospectivemedi-
cal chart assessment of patients with symptoms ofmuscle
pain or weakness or the laboratory finding of an el-
evated creatine kinase level. The frequency of muscle
weakness was not based on a routine physical examina-
tion. Only 1 in 3 subjects had symptoms of weakness,
but the authors could not determine from the medical
charts whether subjects were asked about a decline in the
ability to walk and climb stairs, to lift items previously
raised easily, to arise from a toilet seat or get into and
out of a car, and to participate in recreational activities.
We have found that many patients who were eventually
diagnosed as having a statin-induced myopathy did not
report functional declines unless asked about changes in
specific daily activities.2
The authors state that objectivemuscle tests for a statin-
relatedmyopathy include electromyography andmuscle
biopsy. Little information, however, is available about the
sensitivity of these tests to reveal pathologic findings across
the spectrum of symptoms and signs that have been en-
countered. More important for clinicians in practice is
another objective test—the physician’s ability to over-
come the strength of a patient’s neck flexor muscles, del-
toids, hip flexors tested with the subject supine, and hip
extensors and knee flexors tested with the subject prone,
graded with the standard BritishMedical Council scale.2
Objective functional tests also include the observation
of walking (the gait patternmay reveal a shortened stride
length, unsteadiness on turns, and a waddle from pelvic
muscle paresis) and of the ability to go from sitting to
standing without pushing off from a chair with the arms.
No prospective studies of statins have included rou-
tine testing of muscle strength or muscle enzymes.3 The
sine qua non of a myopathy is diminished proximal
strength. Thus, the incidence ofmyopathy that can cause
proximal weakness and disability may be underappreci-
ated. Until randomized clinical trials of lipid-lowering
agents include routine manual muscle testing or dyna-
mometry to seek the weakness that defines a myopathy,
the numerator for the incidence of this complication can-
not be approximated. In addition, researchers may not
be able to address the genetic and metabolic spectrum
of statin-related muscle dysfunction4 if they do not de-
fine its various phenotypes.
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Observations From a Statin Myopathy Clinic
W e read with great interest the article by Han-sen et al,1 which, to our knowledge, is thefirst published attempt to assess the recov-
ery from a variety of statin-associated muscle disorders.
We would like to add to their report observations from
a statin myopathy clinic that currently follows over 200
patients with these disorders.
The article’s primary finding, that this heterog-
eneous group of patients ex perienced full resolution of
their pain on cessation of statin therapy, conflicts with
our observations.2,3 Hansen et al1 grouped patients with
a number of statin-induced muscle disorders together.
In our subjects, underlying metabolic muscle disorders
and the persistence of weakness is greater in patients with
statin-associated rhabdomyolysis than in patients with
normal creatine kinase myopathy.4 Patients often expe-
rience myalgias and demonstrate abnormalities in car-
diopulmonary exercise for years aftermyositis, while com-
plete resolution of myalgias is typical in patients without
elevated creatinekinase levels.3 Furthermore,whilemuscle
biopsy results in patients with normal creatine kinasemy-
opathy may improve after the myalgias resolve, the tis-
sue often remains myopathic.5
While the patients in the study byHansen et al1 seemed
to resolve their myalgias at subsequent clinic visits, no
objective measures of myopathy such as a dynamom-
etry or cardiopulmonary exercise were made. One can-
not conclude from this article that statin myotoxic ef-
fects are benign simply because those returning to the
clinic stopped complaining of myalgia. It is just as likely
that patients stopped coming to the clinic because their
complaints of myalgia remained untreated. Prospective
studies with objective measures of strength and endur-
ance must be performed before any conclusions about
the reversibility of statin-induced muscle disorders can
be derived.
Finally, the authors’ finding that 43% of patients were
able to tolerate another statin on subsequent rechal-
lenge needs to be scrutinized. Previous work has shown
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